Symbols / CRIS $0.61 +0.53% Curis, Inc.

Healthcare • Biotechnology • United States • NCM
CRIS Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Fundamentals
Scroll to Statements
Market Cap 24.24M Enterprise Value 20.66M Income -7.58M Sales 9.44M Book/sh 0.42 Cash/sh 0.13
Dividend Yield — Payout 0.00% Employees 20 IPO — P/E — Forward P/E -0.63
PEG — P/S 2.57 P/B 1.44 P/C — EV/EBITDA -0.63 EV/Sales 2.19
Quick Ratio 0.36 Current Ratio 0.49 Debt/Eq 29.62 LT Debt/Eq — EPS (ttm) -0.58 EPS next Y -0.96
EPS Growth — Revenue Growth -66.00% Earnings 2026-05-05 ROA -67.17% ROE — ROIC —
Gross Margin -199.68% Oper. Margin -6.65% Profit Margin -80.29% Shs Outstand 39.98M Shs Float 30.89M Short Float 0.16%
Short Ratio 0.26 Short Interest — 52W High 3.13 52W Low 0.49 Beta 3.14 Avg Volume 400.42K
Volume 311.34K Target Price $14.00 Recom Strong_buy Prev Close $0.60 Price $0.61 Change 0.53%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.00
Mean price target
2. Current target
$0.62
Latest analyst target
3. DCF / Fair value
$-4.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.62
Low
$5.00
High
$20.00
Mean
$14.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-20 reit HC Wainwright & Co. Buy → Buy $17
2025-03-31 main HC Wainwright & Co. Buy → Buy $16
2024-12-10 reit HC Wainwright & Co. Buy → Buy $20
2024-11-15 reit HC Wainwright & Co. Buy → Buy $20
2024-11-01 main HC Wainwright & Co. Buy → Buy $20
2024-08-01 reit HC Wainwright & Co. Buy → Buy $26
2024-05-15 main Truist Securities Buy → Buy $26
2024-05-15 reit HC Wainwright & Co. Buy → Buy $26
2024-05-15 reit Cantor Fitzgerald — → Overweight —
2024-05-08 reit HC Wainwright & Co. Buy → Buy $26
2024-02-09 main HC Wainwright & Co. Buy → Buy $26
2023-11-17 init Truist Securities — → Buy $26
News
RSS: Latest CRIS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-31 KAITIN KENNETH I Director — 10,000 $0.55 $5,487
2026-03-20 DENTZER JAMES E Chief Executive Officer — 133,333 — —
2026-03-20 RUBIN MARC R Director — 26,667 — —
2026-03-20 HAMDY AHMED Officer — 66,667 — —
2026-03-20 DUVALL DIANTHA Chief Financial Officer — 66,666 — —
2026-03-20 ZUNG JONATHAN B PH.D. Officer — 66,667 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
9.44
-13.43%
10.91
+8.83%
10.02
-1.37%
10.16
Operating Revenue
9.44
-13.43%
10.91
+8.83%
10.02
-1.37%
10.16
Reconciled Cost Of Revenue
0.04
-54.08%
0.10
-53.77%
0.21
-17.51%
0.26
Gross Profit
9.40
-13.06%
10.81
+10.18%
9.81
-0.95%
9.90
Operating Expense
42.30
-23.58%
55.35
-4.80%
58.14
-7.60%
62.92
Research And Development
28.25
-26.73%
38.56
-2.36%
39.50
-8.74%
43.28
Selling General And Administration
14.05
-16.34%
16.79
-9.96%
18.65
-5.09%
19.65
General And Administrative Expense
14.05
-16.34%
16.79
-9.96%
18.65
-5.09%
19.65
Salaries And Wages
6.72
-22.93%
8.72
-4.90%
9.17
-11.85%
10.40
Other Gand A
6.58
-8.11%
7.16
-14.80%
8.41
+7.26%
7.84
Total Expenses
42.34
-23.63%
55.45
-4.98%
58.35
-7.64%
63.18
Operating Income
-32.90
+26.13%
-44.54
+7.84%
-48.33
+8.84%
-53.02
Total Operating Income As Reported
-5.71
+87.17%
-44.54
+7.84%
-48.33
+8.84%
-53.02
EBITDA
-5.23
+87.72%
-42.57
+5.69%
-45.14
+12.64%
-51.67
Normalized EBITDA
-32.42
+23.85%
-42.57
+5.69%
-45.14
+12.64%
-51.67
Reconciled Depreciation
0.17
-16.75%
0.20
-20.39%
0.26
+9.44%
0.23
EBIT
-5.40
+87.38%
-42.77
+5.77%
-45.39
+12.54%
-51.90
Total Unusual Items
27.19
0.00
—
—
Total Unusual Items Excluding Goodwill
27.19
0.00
—
—
Special Income Charges
27.19
0.00
—
—
Other Special Charges
-27.19
—
—
—
Net Income
-7.58
+82.53%
-43.39
+8.49%
-47.41
+16.34%
-56.67
Pretax Income
-7.58
+82.53%
-43.39
+8.49%
-47.41
+16.34%
-56.67
Net Non Operating Interest Income Expense
-1.87
-262.10%
1.15
+25.46%
0.92
+125.16%
-3.65
Interest Expense Non Operating
2.19
+255.28%
0.61
-69.54%
2.02
-57.68%
4.77
Net Interest Income
-1.87
-262.10%
1.15
+25.46%
0.92
+125.16%
-3.65
Interest Expense
2.19
+255.28%
0.61
-69.54%
2.02
-57.68%
4.77
Interest Income Non Operating
0.32
-82.13%
1.77
-39.82%
2.94
+162.56%
1.12
Interest Income
0.32
-82.13%
1.77
-39.82%
2.94
+162.56%
1.12
Other Income Expense
27.19
—
—
—
Other Non Operating Income Expenses
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-7.58
+82.53%
-43.39
+8.49%
-47.41
+16.34%
-56.67
Net Income From Continuing Operation Net Minority Interest
-7.58
+82.53%
-43.39
+8.49%
-47.41
+16.34%
-56.67
Net Income From Continuing And Discontinued Operation
-7.58
+82.53%
-43.39
+8.49%
-47.41
+16.34%
-56.67
Net Income Continuous Operations
-7.58
+82.53%
-43.39
+8.49%
-47.41
+16.34%
-56.67
Normalized Income
-34.77
+19.86%
-43.39
+8.49%
-47.41
+16.34%
-56.67
Net Income Common Stockholders
-7.58
+82.53%
-43.39
+8.49%
-47.41
+16.34%
-56.67
Diluted EPS
—
-6.88
+23.21%
-8.96
+26.56%
-12.20
Basic EPS
—
-6.88
+23.21%
-8.96
+26.56%
-12.20
Basic Average Shares
—
6.31
+19.14%
5.29
+13.36%
4.67
Diluted Average Shares
—
6.31
+19.14%
5.29
+13.36%
4.67
Diluted NI Availto Com Stockholders
-7.58
+82.53%
-43.39
+8.49%
-47.41
+16.34%
-56.67
Insurance And Claims
0.74
-18.03%
0.90
-15.36%
1.07
-23.99%
1.41
Rent And Landing Fees
—
—
—
—
Rent Expense Supplemental
—
—
—
—
Line Item Trend 2023-12-31
Total Assets
77.28
Current Assets
60.91
Cash Cash Equivalents And Short Term Investments
56.33
Cash And Cash Equivalents
26.68
Other Short Term Investments
29.65
Receivables
2.79
Accounts Receivable
2.79
Prepaid Assets
—
Other Current Assets
1.78
Total Non Current Assets
16.37
Net PPE
3.49
Gross PPE
5.48
Accumulated Depreciation
-1.99
Properties
0.00
Machinery Furniture Equipment
2.17
Other Properties
3.06
Leases
0.26
Goodwill And Other Intangible Assets
8.98
Goodwill
8.98
Investments And Advances
—
Other Non Current Assets
3.90
Total Liabilities Net Minority Interest
57.61
Current Liabilities
22.02
Payables And Accrued Expenses
12.21
Payables
3.17
Accounts Payable
3.17
Current Accrued Expenses
9.04
Pensionand Other Post Retirement Benefit Plans Current
—
Current Debt And Capital Lease Obligation
1.30
Current Capital Lease Obligation
1.30
Other Current Liabilities
8.50
Total Non Current Liabilities Net Minority Interest
35.59
Long Term Debt And Capital Lease Obligation
1.49
Long Term Capital Lease Obligation
1.49
Other Non Current Liabilities
34.10
Stockholders Equity
19.67
Common Stock Equity
19.67
Capital Stock
0.06
Common Stock
0.06
Preferred Stock
0.00
Share Issued
5.89
Ordinary Shares Number
5.89
Treasury Shares Number
0.00
Additional Paid In Capital
1,215.79
Retained Earnings
-1,196.41
Gains Losses Not Affecting Retained Earnings
0.23
Other Equity Adjustments
0.23
Total Equity Gross Minority Interest
19.67
Total Capitalization
19.67
Working Capital
38.89
Invested Capital
19.67
Total Debt
2.79
Capital Lease Obligations
2.79
Net Tangible Assets
10.69
Tangible Book Value
10.69
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-27.20
+31.25%
-39.56
-2.94%
-38.43
+29.27%
-54.34
Cash Flow From Continuing Operating Activities
-27.20
+31.25%
-39.56
-2.94%
-38.43
+29.27%
-54.34
Net Income From Continuing Operations
-7.58
+82.53%
-43.39
+8.49%
-47.41
+16.34%
-56.67
Depreciation Amortization Depletion
0.17
-16.75%
0.20
-20.39%
0.26
+9.44%
0.23
Depreciation And Amortization
0.17
-16.75%
0.20
-20.39%
0.26
+9.44%
0.23
Other Non Cash Items
-25.56
-1889.64%
1.43
+42.23%
1.00
-44.74%
1.82
Stock Based Compensation
4.02
-32.21%
5.93
-1.22%
6.00
-11.14%
6.75
Operating Gains Losses
—
—
—
—
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
1.75
+147.09%
-3.72
-233.72%
2.78
+140.76%
-6.82
Change In Receivables
-1.03
-85.95%
-0.56
-406.63%
0.18
-27.31%
0.25
Changes In Account Receivables
-1.03
-85.95%
-0.56
-406.63%
0.18
-27.31%
0.25
Change In Prepaid Assets
1.57
+1030.94%
0.14
-65.68%
0.41
+117.79%
-2.28
Change In Payables And Accrued Expense
2.55
+222.58%
-2.08
-162.19%
3.34
+185.99%
-3.88
Change In Payable
—
—
—
-3.88
Change In Account Payable
—
—
—
-3.88
Change In Other Current Assets
—
—
—
-2.02
Change In Other Current Liabilities
-1.34
-9.24%
-1.22
-6.63%
-1.15
-26.46%
-0.91
Investing Cash Flow
2.50
-91.51%
29.44
-22.08%
37.79
+14.42%
33.02
Cash Flow From Continuing Investing Activities
2.50
-91.51%
29.44
-22.08%
37.79
+14.42%
33.02
Net PPE Purchase And Sale
—
—
0.00
+100.00%
-0.42
Purchase Of PPE
—
—
0.00
+100.00%
-0.42
Capital Expenditure
—
—
—
-0.42
Net Investment Purchase And Sale
0.00
-100.00%
29.44
-22.08%
37.79
+13.00%
33.44
Purchase Of Investment
0.00
+100.00%
-18.10
+74.27%
-70.34
-13.45%
-62.00
Sale Of Investment
0.00
-100.00%
47.54
-56.03%
108.13
+13.29%
95.44
Net Business Purchase And Sale
2.50
0.00
—
—
Financing Cash Flow
9.77
+184.11%
3.44
-54.66%
7.58
+774.28%
0.87
Cash Flow From Continuing Financing Activities
9.77
+184.11%
3.44
-54.66%
7.58
+774.28%
0.87
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
15.35
+27.69%
12.02
-14.83%
14.12
+141.65%
5.84
Proceeds From Stock Option Exercised
—
—
—
0.25
Net Other Financing Charges
-5.59
+34.93%
-8.59
-31.34%
-6.54
-31.40%
-4.97
Changes In Cash
-14.94
-123.46%
-6.68
-196.42%
6.93
+133.90%
-20.45
Beginning Cash Position
20.54
-24.55%
27.23
+34.16%
20.29
-50.19%
40.74
End Cash Position
5.61
-72.71%
20.54
-24.55%
27.23
+34.16%
20.29
Free Cash Flow
-27.20
+31.25%
-39.56
-2.94%
-38.43
+29.80%
-54.75
Interest Paid Supplemental Data
1.53
+232.75%
0.46
-80.46%
2.36
-42.63%
4.11
Amortization Of Securities
0.00
+100.00%
-0.02
+98.49%
-1.06
-401.71%
0.35
Common Stock Issuance
15.35
+27.69%
12.02
-14.83%
14.12
+141.65%
5.84
Issuance Of Capital Stock
15.35
+27.69%
12.02
-14.83%
14.12
+141.65%
5.84
Sale Of Business
2.50
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category